Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) have received a consensus rating of “Buy” from the nineteen analysts that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $78.47.

Several equities research analysts have weighed in on RARE shares. Morgan Stanley raised shares of Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $68.00 to $83.00 in a research note on Wednesday, March 27th. Credit Suisse Group reaffirmed a “hold” rating and issued a $59.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 20th. Raymond James reaffirmed an “outperform” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 22nd. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Finally, BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th.

In other news, CFO Shalini Sharp sold 14,800 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $70.00, for a total transaction of $1,036,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 468 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $68.30, for a total transaction of $31,964.40. The disclosure for this sale can be found here. Insiders own 7.80% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Clearbridge Investments LLC increased its position in shares of Ultragenyx Pharmaceutical by 0.3% during the first quarter. Clearbridge Investments LLC now owns 1,013,273 shares of the biopharmaceutical company’s stock worth $70,281,000 after acquiring an additional 3,237 shares in the last quarter. Metropolitan Life Insurance Co NY increased its position in shares of Ultragenyx Pharmaceutical by 8.2% during the first quarter. Metropolitan Life Insurance Co NY now owns 16,653 shares of the biopharmaceutical company’s stock worth $1,155,000 after acquiring an additional 1,268 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth about $3,468,000. BlueCrest Capital Management Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth about $480,000. Finally, Man Group plc grew its position in Ultragenyx Pharmaceutical by 80.5% in the 1st quarter. Man Group plc now owns 77,705 shares of the biopharmaceutical company’s stock worth $5,389,000 after purchasing an additional 34,662 shares in the last quarter.

RARE opened at $58.17 on Tuesday. Ultragenyx Pharmaceutical has a 1-year low of $37.44 and a 1-year high of $90.98. The company has a quick ratio of 11.60, a current ratio of 11.77 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -7.87 and a beta of 2.20.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.73) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 550.30% and a negative return on equity of 51.00%. The company had revenue of $18.17 million during the quarter, compared to the consensus estimate of $18.75 million. During the same period last year, the firm posted $0.63 earnings per share. The company’s revenue for the quarter was up 70.1% on a year-over-year basis. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -6.99 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Read More: Dividend Aristocrat Index

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.